All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

1,560

2012 to 2026

Breakthrough

316

Accelerated

131

Priority review

1560

Orphan

759

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
2012426
2013398
20145417
20155818
20165520
20178633
20189948
201910032
20208653
20218653
20228433
20237734
20248232
20257247
20265947

1,560 approvals

Newest first. Hover a badge for what it means.

  • Gazyva (Obinutuzumab) · GenentechNov 13, 2026
    Efficacy supplement 44 · BLA 125486Priority review
  • Imfinzi (Durvalumab) · Astrazeneca Uk LTDNov 13, 2026
    Efficacy supplement 59 · BLA 761069Priority review
  • Zurzuvae (Zuranolone) · BiogenNov 13, 2026
    Efficacy supplement 4 · NDA 217369Priority review
  • Sunharbo (Asundexian) · Bayer HealthcareNov 9, 2026
    Original approval · NDA 221291NovelPriority reviewApproval letter

    To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack

  • Rybrevant Faspro (Amivantamab and Hyaluronidase-Lpuj) · Janssen BiotechNov 5, 2026
    Efficacy supplement 2 · BLA 761433Priority reviewApproval letter
  • Talzenna (Talazoparib Tosylate) · PfizerOct 26, 2026
    Efficacy supplement 14 · NDA 211651Priority reviewApproval letter
  • Talzenna (Talazoparib Tosylate) · PfizerOct 26, 2026
    Efficacy supplement 4 · NDA 217439Priority reviewApproval letter
  • Skyrizi (Risankizumab-Rzaa) · Abbvie INCOct 23, 2026
    Efficacy supplement 53 · BLA 761105Priority reviewOrphanApproval letter
  • Awiqli Flextouch (Insulin Icodec) · Novo Nordisk INCOct 23, 2026
    Efficacy supplement 1 · BLA 761326Priority reviewApproval letter
  • Ultomiris (Ravulizumab-Cwvz) · Alexion PharmOct 21, 2026
    Efficacy supplement 46 · BLA 761108Priority reviewOrphanApproval letter
  • Hibsago (Bepirovirsen Sodium) · GlaxosmithklineOct 20, 2026
    Original approval · NDA 221276NovelPriority reviewApproval letter

    To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy

  • Jemperli (Dostarlimab-Gxly) · GlaxosmithklineOct 19, 2026
    Efficacy supplement 15 · BLA 761174Priority reviewApproval letter
  • Enspryng (Satralizumab) · GenentechOct 15, 2026
    Efficacy supplement 8 · BLA 761149Priority reviewApproval letter
  • Hovilpri (Pritelivir Mesylate) · Aicuris Anti-InfectOct 9, 2026
    Original approval · NDA 221154NovelPriority reviewApproval letter

    To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies

  • Tecentriq (Atezolizumab) · Genentech INCOct 8, 2026
    Efficacy supplement 65 · BLA 761034Priority reviewApproval letter
  • Tecentriq Hybreza (Atezolizumab and Hyaluronidase-Tqjs) · Genentech INCOct 8, 2026
    Efficacy supplement 11 · BLA 761347Priority reviewApproval letter
  • Camzyos (Mavacamten) · BristolSep 30, 2026
    Efficacy supplement 13 · NDA 214998Priority reviewOrphanApproval letter
  • Emcitate (Tiratricol) · Rare ThyroidSep 28, 2026
    Original approval · NDA 220963NovelPriority reviewOrphanApproval letter

    To treat peripheral thyrotoxicosis in patients with MCT8 deficiency

  • Atebrioz (Zilurgisertib Fumarate) · MirumSep 25, 2026
    Original approval · NDA 221198NovelPriority reviewOrphanApproval letter

    To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva

  • Gazyva (Obinutuzumab) · GenentechSep 25, 2026
    Efficacy supplement 43 · BLA 125486Priority reviewOrphanApproval letter
  • Lyrfigtu (Lirafugratinib Hydrochloride) · ElevarSep 23, 2026
    Original approval · NDA 220425NovelPriority reviewOrphanApproval letter

    To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement

  • Aqneursa (Levacetylleucine) · IntrabioSep 18, 2026
    Efficacy supplement 2 · NDA 219132Priority reviewOrphanApproval letter
  • Kerendia (Finerenone) · Bayer HlthcareSep 16, 2026
    Efficacy supplement 11 · NDA 215341Priority reviewApproval letter
  • Isembyld (Apitegromab-Mstn) · Scholar Rock INCSep 11, 2026
    Original approval · BLA 761463NovelPriority reviewOrphanApproval letter

    To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment

  • Joenja (Leniolisib Phosphate) · PharmingSep 11, 2026
    Efficacy supplement 6 · NDA 217759Priority reviewOrphanApproval letter
  • Pixclara (Floretyrosine F-18) · TelixSep 11, 2026
    Original approval · NDA 218592NovelPriority reviewOrphanApproval letter

    To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations

  • Hyrnuo (Sevabertinib) · Bayer HealthcareSep 9, 2026
    Efficacy supplement 1 · NDA 219972Priority reviewOrphanApproval letter
  • Zanvastro (Zilganersen Sodium) · Ionis Pharms INCSep 3, 2026
    Original approval · NDA 220210NovelPriority reviewOrphanApproval letter

    To treat Alexander disease in pediatric and adult patients

  • Mimrylo (Rusfertide Acetate) · Takeda Pharms AmAug 28, 2026
    Original approval · NDA 220605NovelPriority reviewOrphanApproval letter

    To treat erythrocytosis in adults with polycythemia vera

  • Bixlenvo (Bictegravir Sodium, Lenacapavir Sodium) · Gilead Sciences INCAug 27, 2026
    Original approval · NDA 221104Priority reviewApproval letter
  • Lisraya (Brepocitinib Tosylate) · Priovant TherapAug 27, 2026
    Original approval · NDA 220106NovelPriority reviewOrphanApproval letter

    To treat dermatomyositis in adults

  • Rasonque (Daraxonrasib) · Revolution MedicinesAug 26, 2026
    Original approval · NDA 220910NovelPriority reviewOrphanApproval letter

    To treat metastatic pancreatic cancer

  • Tevimbra (Tislelizumab-Jsgr) · BeigeneAug 25, 2026
    Efficacy supplement 18 · BLA 761232Priority reviewOrphanApproval letter
  • Ziihera (Zanidatamab-Hrii) · Jazz PharmsAug 25, 2026
    Efficacy supplement 2 · BLA 761416Priority reviewOrphanApproval letter
  • Tivicay (Dolutegravir Sodium) · Viiv HlthcareAug 25, 2026
    Efficacy supplement 34 · NDA 204790Priority reviewApproval letter
  • Tivicay Pd (Dolutegravir Sodium) · Viiv HlthcareAug 25, 2026
    Efficacy supplement 7 · NDA 213983Priority reviewApproval letter
  • Imaavy (Nipocalimab-Aahu) · Janssen BiotechAug 24, 2026
    Efficacy supplement 2 · BLA 761430Priority reviewOrphanApproval letter
  • Pasatru (Garetosmab-Grts) · Regeneron Pharmaceuticals, INCAug 19, 2026
    Original approval · BLA 761508NovelPriority reviewOrphanApproval letter

    To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva

  • Zenbexus (Iberdomide Hydrochloride) · Bristol Myers SquibbAug 13, 2026
    Original approval · NDA 221075NovelPriority reviewOrphanApproval letter

    To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent

  • Orzeyful (Oveporexton) · Takeda Pharms USAAug 5, 2026
    Original approval · NDA 220860NovelPriority reviewOrphanApproval letter

    To treat narcolepsy type 1

  • Simtriyo (Centanafadine Hydrochloride) · OtsukaJul 24, 2026
    Original approval · NDA 218145NovelPriority reviewApproval letter

    To treat attention-deficit hyperactivity disorder

  • Macrilen (Macimorelin Acetate) · Aeterna ZentarisJul 23, 2026
    Efficacy supplement 5 · NDA 205598Priority reviewOrphanApproval letter
  • Fabhalta (Iptacopan Hydrochloride) · NovartisJul 16, 2026
    Efficacy supplement 7 · NDA 218276Priority reviewApproval letter
  • Lipfendra (Enlicitide Decanoate) · MsdJul 15, 2026
    Original approval · NDA 220848NovelPriority reviewApproval letter

    To reduce low-density lipoprotein cholesterol

  • Revtorpyk (Gedatolisib) · CelcuityJul 14, 2026
    Original approval · NDA 219908NovelPriority reviewApproval letter

    In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting

  • Leqembi Iqlik (Lecanemab-Irmb) · Eisai INCJul 13, 2026
    Efficacy supplement 1 · BLA 761375Priority reviewApproval letter
  • Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp DohmeJul 10, 2026
    Efficacy supplement 12 · BLA 761467Priority reviewApproval letter
  • Padcev (Enfortumab Vedotin-Ejfv) · AstellasJul 10, 2026
    Efficacy supplement 37 · BLA 761137Priority reviewApproval letter
  • Keytruda (Pembrolizumab) · Merck Sharp DohmeJul 10, 2026
    Efficacy supplement 194 · BLA 125514Priority reviewApproval letter
  • Trutakna (Atacicept-Vymj) · Vera Therapeutics Inc.Jul 7, 2026
    Original approval · BLA 761486NovelPriority reviewApproval letter

    To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression

Page 1 of 32Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.